Takhzyro
What Takhzyro is used for
Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Takhzyro
- Active substance
- lanadelumab
- Disease area
- Angioedemas, Hereditary
- Medicine group
- Other hematological agents
- ATC code
- B06AC05
- Marketing authorisation holder
- Takeda Pharmaceuticals International AG Ireland Branch
- Authorised in the EU since
- 2018
Official information
In the USA
Same active substance: Takhzyro
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Takhzyro used for?
Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.
What is the active substance in Takhzyro?
Takhzyro contains lanadelumab.
Who makes Takhzyro?
The EU marketing authorisation holder is Takeda Pharmaceuticals International AG Ireland Branch.
Is Takhzyro an orphan medicine?
Yes. Takhzyro is designated an orphan medicine in the EU, for a rare disease (Angioedemas, Hereditary).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU